Keyphrases
Additional Injection
16%
Administrative Claims Data
16%
Aflibercept
16%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
50%
Anti-VEGF Therapy
100%
Bevacizumab
16%
Clinical Modification
16%
Clinical Trials
16%
Corticosteroids
33%
Diabetic Macular Edema
100%
Focal Laser
16%
Generalized Linear Regression
16%
Insurance
16%
International Classification of Diseases
16%
Laser Procedure
33%
Mann-Kendall Test
16%
Medicaid
16%
Medicare
33%
Nationally Representative Sample
16%
Negative Binomial
16%
Ninth Edition
16%
Ranibizumab
16%
Recently Diagnosed
100%
Regression Logistic
16%
Retina Specialists
33%
Retrospective Cohort Study
16%
Treatment Patterns
100%
Treatment Standards
16%
Year of Diagnosis
16%
Yearly Trend
16%
Medicine and Dentistry
Aflibercept
11%
Bevacizumab
11%
Clinical Trial
11%
Diabetic Macular Edema
100%
Endothelial Cell Growth Factor
11%
International Classification of Diseases
11%
Linear Regression Analysis
11%
Medicare
22%
Ranibizumab
11%
Retrospective Cohort Study
11%
Vasculotropin
100%